Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027

‘Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027
Atopic Dermatitis- Disease Understanding and Treatment Algorithm
The Atopic Dermatitis market report gives the thorough understanding of the Atopic Dermatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Atopic Dermatitis in the US, Europe, and Japan.

Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Expert, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.

Atopic Dermatitis Drug Chapters
This segment of the Atopic Dermatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment of Atopic Dermatitis mainly include Dupixent (dupilumab), Eucrisa (crisaborole), Desonate (desonide), Verdeso (desonide), Elidel (pimecrolimus), Protopic (tacrolimus), Allegra (Fexofenadine hydrochloride) and Neoral solution (cyclosporine).
Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), ZPL-389 (Novartis), NST-141 (Nippon Shinyaku), etc., have been covered in the report.

Atopic Dermatitis Market Outlook
The Atopic Dermatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to Expert, the global market of Atopic Dermatitis was estimated to be USD 2.2 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Atopic Dermatitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Dermatitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Atopic Dermatitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Atopic Dermatitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving the Atopic Dermatitis market
• Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis market
• To understand the future market competition in the Atopic Dermatitis market.
1. Report Introduction
2. Atopic Dermatitis Market Overview at a Glance
2.1. Market Share Distribution of Atopic Dermatitis in 2017
2.2. Market Share Distribution of Atopic Dermatitis in 2027
3. Disease Background and Overview
3.1. Etiology
3.2. Risk Factors
3.3. Pathophysiology
3.4. Atopic Dermatitis
3.4.1. Pruritus Associated with Atopic Dermatitis
3.4.2. Diagnosis
4. Epidemiology and Patient Population
4.1. Disease Definition
4.2. Population and Forecast Parameters
4.3. Population Methods
4.3.1. Total prevalent cases in US
4.3.2. EU5
4.3.3. Japan
4.4. Prevalent Population of Atopic Dermatitis in 7MM
4.5. Prevalent Population of Atopic Dermatitis in United States
4.6. Prevalent Population of Atopic Dermatitis in Germany
4.7. Prevalent Population of Atopic Dermatitis in France
4.8. Prevalent Population of Atopic Dermatitis in Italy
4.9. Prevalent Population of Atopic Dermatitis in Spain
4.10. Prevalent Population of Atopic Dermatitis in United Kingdom
4.11. Prevalent Population of Atopic Dermatitis in Japan
4.12. Prevalent Population of Atopic Dermatitis by Severity in 7MM
4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM
4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM
4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM
5. Treatment Practices
6. Treatment Algorithm
6.1. Treatment Goals
6.2. Treatment Guidelines by American Academy of Dermatology
6.3. Japanese Guidelines for Atopic Dermatitis 2017
6.4. Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis): European Dermatology Forum
7. Treatment Failure
7.1. Approved Drugs for Atopic Dermatitis
8. Emerging Therapies
9. Nemolizumab: Galderma Pharma
9.1. Product Description
9.2. Research and Development
9.3. Product Development Activities
10. Tralokinumab: LEO Pharma
10.1. Product Description
10.2. Research and Development
10.3. Product Development Activities
11. Tradipitant: Vanda Pharmaceuticals
11.1. Product Description
11.2. Research and Development
11.3. Product Development Activities
12. ZPL-389: Novartis
12.1. Product Description
12.2. Research and Development
12.3. Product Development Activities
13. NST-141: Nippon Shinyaku
13.1. Product Description
13.2. Research and Development
13.3. Product Development Activities
14. Serlopitant: Menlo Therapeutics
14.1. Product Description
14.2. Research and Development
14.3. Product Development Activities
15. DS107: DS Biopharma
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities
16. Asimadoline: Tioga Pharmaceuticals
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities
17. GSK2894512: GlaxoSmithKline
17.1. Product Description
17.2. Research Development Activities
17.3. Product Development Activities
18. Lebrikizumab: Roche
18.1. Product Description
18.2. Research and Development
19. DMT210: Dermata Therapeutics
19.1. Product Description
19.2. Research and Development
19.3. Product Development Activities
20. RVT-501: Roivant Sciences
20.1. Product Description
20.2. Research and Development
20.3. Product Development Activities
21. OPA-15406: Otsuka Pharmaceutical
21.1. Product Description
21.2. Research and Development
21.3. Product Development Activities
22. Current Unmet Need
23. Atopic Dermatitis: Market Analysis
23.1. Market Outlook-7MM
23.2. Market size of Atopic Dermatitis in 7MM
24. Atopic Dermatitis: United States Market Outlook
24.1. United States Market size
25. Atopic Dermatitis: EU5 Market Outlook
25.1. Germany Market size
25.2. France Market size
25.3. Italy Market size
25.4. Spain Market size
25.5. United Kingdom Market size
26. Atopic Dermatitis: Japan Market Outlook
26.1. Japan Market size
27. Market Drivers
28. Market Barriers
29. Expert Opinions
30. Views on Current treatment options
31. Views on emerging therapies
32. Appendix
33. Report Methodology
33.1. Source Used
34. DelevInsight Capabilities
35. Disclaimer
36. About DelveInsight

List of Figures, Tables and Charts Available in Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027

Table 1: Targets focused by companies
Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger
Table 3: Hanifin and Rajka Diagnostic Criteria
Table 4: United Kingdom Working Party diagnostic criteria
Table 5: American Academy of Dermatology Diagnostic Criteria
Table 6: Japanese Dermatological Association Diagnostic Criteria
Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027)
Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027)
Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM
Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM
Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM
Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Table 21:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis
Table 23: Topical Calcineurin Inhibitors (TCIs)
Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
Table 25: Oral Corticosteroids
Table 26: Biologic medications
Table 27: Non-approved systemic immunomodulating agents
Table 28: Reasons for noncompliance with medication
Table 29: Emerging therapies
Table 30: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
Table 31: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027)
Table 32: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027)
Table 33: Market Size of Atopic Dermatitis in France, USD Million (2016-2027)
Table 34: Market Size of Atopic Dermatitis in Italy, USD Million (2016-2027)
Table 35: Market Size of Atopic Dermatitis in Spain , USD Million (2016-2027)
Table 36: Market Size of Atopic Dermatitis in United Kingdom, USD Million (2016-2027)
Table 37:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027)
Figure 1: Risk Factors for Atopic Dermatitis
Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD)
Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis
Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027)
Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027)
Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027)
Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027)
Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Figure 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Figure 20: General Treatment for Atopic Dermatitis
Figure 21: First Line and second line treatment of Atopic Dermatitis
Figure 22: Current stepped treatment options for Atopic dermatitis
Figure 23: Current Unmet Need for Atopic Dermatitis
Figure 24: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
Figure 25: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027)
Figure 26: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027)
Figure 27: Market Size of Atopic Dermatitis in France, USD Million (2016-2027)
Figure 28: Market Size of Dermatitis in Italy, USD Million (2016-2027)
Figure 29: Market Size of Atopic Dermatitis in Spain, USD Million (2016-2027)
Figure 30: Market Size of Atopic Dermatitis in United Kingdom , USD Million (2016-2027)
Figure 31:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027)